JC virus granule cell neuronopathy and GCN–IRIS under natalizumab treatment |
| |
| Authors: | Sven Schippling MD Christian Kempf MD Fabian Büchele MD Ivan Jelcic PhD Oliver Bozinov MD Adriano Bont MD Michael Linnebank MD Mireia Sospedra PhD Michael Weller MD Herbert Budka MD Roland Martin MD |
| |
| Institution: | 1. Neuroimmunology and Multiple Sclerosis Research Section, Department of Neurology, University Hospital Zurich, , Zurich;2. Department of Neurology, University Hospital Zurich, , Zurich;3. Institute of Neuropathology, University Hospital Zurich, , Zurich;4. Department of Neurosurgery, University Hospital Zurich, , Zurich;5. Private Neurology Clinic, , Winterthur, Switzerland |
| |
| Abstract: | Progressive multifocal leukoencephalopathy is the most common clinical presentation of JC virus (JCV)‐associated central nervous system (CNS) disease and has emerged as a major safety concern in multiple sclerosis patients treated with the monoclonal antibody natalizumab. Here we report clinical, radiological, and histological findings of a case of cerebellar granule cell neuronopathy (GCN), a JCV‐associated CNS disease, so far unreported amongst patients treated with natalizumab. GCN should be considered as a JCV CNS manifestation in patients with newly developed, progressive cerebellar signs under natalizumab treatment, especially in cases where cerebellar atrophy can be visualized by magnetic resonance imaging. Ann Neurol 2013;74:622–626 |
| |
| Keywords: | |
|
|
